Learn More
Interleukin-6 (IL-6) is a potent mediator of inflammatory and immune responses, and a validated target for therapeutic intervention of inflammatory diseases. Previous studies have shown that SL1026, a slow off-rate modified aptamer (SOMAmer) antagonist of IL-6, neutralizes IL-6 signaling in vitro. In the present study, we show that SL1026 delays the onset(More)
Interferon alpha (IFNα) is one of the most famous drugs for the treatment of chronic hepatitis C and various types of human malignancy. Protein drugs, including IFNα, are generally administered by subcutaneous or intramuscular injection due to their poor permeability and low stability in the bloodstream or gastrointestinal tract. Therefore, in the present(More)
The beta-2 integrin consists of lymphocyte function-antigen-1 (LFA-1, CD11a/CD18) which binds to the major ligand intracellular adhesion molecules 1 and 2 (ICAM-1 and ICAM-2), Mac-1 (CD11b/CD18, ligand iC3b) and p150,95 (CD11c/CD18, ligand iC3b). These molecules function not only as adhesion molecules but as signal transduction agents. To investigate the(More)
We report the immunological characteristics of human peripheral T lymphocytes and behavior of PHA-stimulated lymphocytes in Type II diabetes mellitus, investigated two-color flow cytometry. The subsets of Leu11+Leu7+, Leu11-Leu7+ and Leu7+Leu2+ were decreased significantly in peripheral Natural Killer cells. After PHA stimulation the T-cell subsets(More)
  • 1